Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
대표청구항▼
The invention claimed is: 1. A compound which directly inhibits IRE-1α activity in vitro and is represented by structural formula (B): or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, phenyl or an optionally benzofused five- or six-membered heterocycle, wherein the
The invention claimed is: 1. A compound which directly inhibits IRE-1α activity in vitro and is represented by structural formula (B): or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, phenyl or an optionally benzofused five- or six-membered heterocycle, wherein the phenyl or the optionally benzofused five- or six-membered heterocycle is optionally substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, R2 is phenyl or an optionally benzofused five- or six-membered heterocycle, wherein the phenyl or the optionally benzofused five- or six-membered heterocycle is optionally substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, R3 is hydrogen, halogen, —NO2, C1-C3 linear or branched alkyl, C1-C3 linear or branched alkoxy, C1-C3 linear or branched hydroxyl alkyl, and R4 is hydrogen, 2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable vehicle. 3. A method of inhibiting the activity of IRE1-α comprising contacting the IRE1-α enzyme with a compound of claim 1. 4. The method of claim 3 wherein the compound is the compound of claim 21. 5. The method of claim 3 wherein the compound is the compound of claim 22. 6. The compound of claim 1 wherein R1, R3, and R4 are hydrogen. 7. The compound of claim 6 wherein R2 is a five-membered heterocycle. 8. The compound of claim 7 wherein the five-membered heterocycle is substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, 9. The compound of claim 1 wherein R2 is a five-membered heterocycle. 10. The compound of claim 9 wherein R2 is 11. The compound of claim 9 wherein the five-membered heterocycle is substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, 12. A compound which has the structural formula: 13. The pharmaceutical composition of claim 2 wherein R1, R3, and R4 are hydrogen. 14. The pharmaceutical composition of claim 13 wherein R2 is a five-membered heterocycle. 15. The pharmaceutical composition of claim 14 wherein the five-membered heterocycle is substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, 16. The pharmaceutical composition of claim 2 wherein R2 is a five-membered heterocycle. 17. The pharmaceutical composition of claim 16 wherein the five-membered heterocycle is substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, 18. A pharmaceutical composition comprising: a compound which has the structural formula or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle. 19. The method of claim 3 wherein R1, R3, and R4 are hydrogen. 20. The method of claim 19 wherein R2 is a five-membered heterocycle. 21. The method of claim 19 wherein the five-membered heterocycle is substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, 22. The method of claim 3 wherein R2 is a five-membered heterocycle. 23. The method of claim 22 wherein the five-membered heterocycle is substituted with —CH3OH, —CHO, —OCH3, halogen, —OH, —CH3, 24. A method of inhibiting the activity of IRE1-α comprising contacting the IRE1-α enzyme with a compound having the structural formula or a pharmaceutically acceptable salt thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (88)
Lafon Louis (Paris FRX), (2,4,6-trimethoxyphenyl)-(3-piperidinopropyl)-ketone derivatives.
Uno Hitoshi (Takatsuki JPX) Karasawa Tadahiko (Toyonaka JPX) Kon Tatsuya (Ashiya JPX) Ito Tsugutaka (Suita JPX), 1-(2,3-Dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone and anti-spastic use thereof.
Vicari Richard (Chatham Township ; Morris County NJ) Aslam Mohammad (Corpus Christi TX) Ray Wilson B. (Beeville TX) Davenport Kenneth G. (Hofheim DEX) Dammel Ralph (Mainz-Bretzenheim DEX) Lingnau Jue, 3,5-disubstituted-4-acetoxystyrene and process for its production.
Englert Heinrich C. (Hofheim am Taunus DEX) Lang Hans-Jochen (Hofheim am Taunus DEX) Mania Dieter (Kelkheim DEX) Bickel Martin (Frankfurt am Main DEX), 6-sulfoxyphenol derivatives, their preparation and their use as cytoprotective agents.
Abraham Donald J. (Midlothian VA) Boyiri Telih (Richmond VA) Safo Martin (Richmond VA) Danso-Danquah Richmond (Richmond VA), Aldehydic agents for allosteric modification of hemoglobin.
Magnus Pfahl ; Xian-Ping Lu ; Darryl Rideout ; Hongyue Zhang, Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias.
Wang, Yan; Cai, Sui Xiong; Lan, Nancy C.; Keana, John F. W.; Ilyin, Victor I.; Weber, Eckard, Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof.
Kamitamari,Masashi; Suzukamo,Gohfu; Yamamoto,Michio; Hagiya,Koji; Itagaki,Makoto, Chiral copper complex and production processes thereof and using the same.
Babu J. Mavunkel ; John A. Lewicki ; David Y. Liu ; George F. Schreiner ; John J. Perumattam, Compounds and methods to treat cardiac failure and other disorders.
Baratz Brenda S. (Indianapolis IN) Phillips Robert A. (Indianapolis IN) Steward David L. (Carmel IN), Inhibition of enveloped viruses with phenyl ketones.
Buchwald Stephen L. ; Old David W. ; Wolfe John P. ; Palucki Michael ; Kamikawa Ken, Ligands for metals and improved metal-catalyzed processes based thereon.
Abraham Donald J. (Midlothian VA) Harris Louis S. (Richmond VA) Meade B. J. (Richmond VA) Munson Albert E. (Midlothian VA) Swerdlow Paul S. (Richmond VA) Patrick Graham A. (Richmond VA), Method of calming or sedating an animal with a hydroxy benzaldehyde compound.
Langbein Adolf (Gau-Algesheim DEX) Weber Karl-Heinz (Gau-Algesheim DEX) Boke Karin (Ingelheim am Rhein DEX), N-[1-(3-Benzoyl-propyl)-4-piperidyl]-sulfonic acid amides and salts thereof.
Formanek Karel (Serezin Du Rhone FRX) Michelet Daniel (Tassin La Demi-Lune FRX) Petre Dominique (Lyons FRX), Preparation of polyphenols by oxidation of hydroxybenzaldehydes.
Casnati Giuseppe (Parma ITX) Casiraghi Giovanni (Parma ITX) Puglia Giuseppe (Reggio Emilia ITX) Sartori Giovanni (Vicobellignano ITX) Terenghi Giuliana (Parma ITX), Process for preparing 2-hydroxybenzoic aldehydes.
Seng Florin (Bergisch-Gladbach DEX) Bremen Josef (Leverkusen DEX), Process for the preparation of b
상세보기
Schnatterer Albert (Leverkusen DEX) Fiege Helmut (Leverkusen DEX) Neumann Karl-Heinz (St. Augustin DEX), Process for the preparation of o-hydroxy-benzaldehydes.
Metivier Pascal,FRX ; Maliverney Christian,FRX ; Denis Philippe,FRX, Process for the selective preparation of a 2-hydroxybenzoic acid and a 4-hydroxybenzaldehyde and derivatives thereof.
Batt Douglas G. (Wilmington DE) Pinto Donald J. P. (Newark DE) Orwat Michael J. (Wilmington DE) Petraitis Joseph J. (Glenmoore PA) Pitts William J. (Newark DE), Prostaglandin synthase inhibitors.
Clark Michael T. (Downingtown) Gyurik Robert J. (Downingtown) Lewis Sharon K. (Conshohocken) Murray Marianne C. (Malvern) Raymond Matthew J. (St. Davids PA), Stabilized somatotropin for parenteral administration.
Donald J. Abraham ; Gajanan S. Joshi ; Stephen J. Hoffman ; Melissa Grella ; Richmond Danso-Danquah ; Amal Yousseff ; Martin Safo ; Sanjeev Kulkarni, Substituted chiral allosteric hemoglobin modifiers.
Chang Michael N. (Westfield NJ) Jensen Norman P. (Princeton NJ) Hammond Milton L. (Somerville NJ) Zambias Robert A. (Springfield NJ) McDonald John (Indianapolis IN) Rupprecht Kathleen M. (Cranford NJ, Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents.
Lentz Carl M. (Kingsport TN) Gustafson Bruce L. (Kingsport TN) Van Sickle Dale E. (Kingsport TN) Bowers ; Jr. Joseph S. (Kingsport TN), Synthesis of phenylhydroquinones.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.